← Leaderboards
Lai-Xi Wang
University Of Chicago
$15,960,729
Attributed
$17,284,756
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$17,284,756 · 10
By mechanism
R01$16,163,506 · 7
R21$1,121,250 · 3
Top collaborators
- Dominique M Missiakas5 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Dominique M Missiakas$23,756,875
- Michael Zdenek David$7,385,677
Others in their field
Top investigators on “Glycosylation”
- John M Lachin · George Washington University$134,552,372
- David M Nathan · Massachusetts Institute Of Technology$122,159,340
- Rose A Gubitosi-Klug · Case Western Reserve University$60,881,424
- Rohit Varma · University Of Southern California$43,479,151
- Anastassios G Pittas · Tufts Medical Center$32,774,287
- Ajit P Varki · University Of California San Diego$22,836,403
Research focus
GlycosylationAntibodiesPolysaccharidesBaseEngineeringHeterogeneityGlycoproteinsStructureSerumMutantEndoglycosidasesImmunoglobulin GGlycopeptidesProteinsRecombinantsAffectAntigensComplexBiologicalSiteImmune ResponseHiv-1Half-LifeHydrolysis
Grant awards (50)
Glycoengineering of antibodies to modulate immune functions$540,922
R01 · FY2024 · AI · contact PI
Antibody therapy of MRSA colonization and infection$540,443
R01 · FY2024 · AI
Glycoengineering of antibodies to modulate immune functions$541,031
R01 · FY2023 · AI · contact PI
Antibody therapy of MRSA colonization and infection$524,243
R01 · FY2023 · AI
Glycoengineering of antibodies to modulate immune functions$626,390
R01 · FY2022 · AI · contact PI
Antibody therapy of MRSA colonization and infection$524,243
R01 · FY2022 · AI
Glycoengineering of antibodies to modulate immune functions$626,390
R01 · FY2021 · AI · contact PI
Antibody therapy of MRSA colonization and infection$522,623
R01 · FY2021 · AI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$307,955
R01 · FY2021 · GM · contact PI
Glycoengineering of antibodies to modulate immune functions$662,880
R01 · FY2020 · AI · contact PI
Antibody therapy of MRSA colonization and infection$536,503
R01 · FY2020 · AI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$307,976
R01 · FY2020 · GM · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$301,550
R01 · FY2020 · GM · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$307,996
R01 · FY2019 · GM · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$301,577
R01 · FY2019 · GM · contact PI
Synthetic HIV Vaccine Targeting Glycopeptide Neutralization Epitopes$455,882
R01 · FY2018 · AI · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$308,016
R01 · FY2018 · GM · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$301,370
R01 · FY2018 · GM · contact PI
Synthetic HIV Vaccine Targeting Glycopeptide Neutralization Epitopes$451,365
R01 · FY2017 · AI · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$301,402
R01 · FY2017 · GM · contact PI
Synthetic HIV Vaccine Targeting Glycopeptide Neutralization Epitopes$455,332
R01 · FY2016 · AI · contact PI
Covergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$291,474
R01 · FY2016 · GM · contact PI
Synthetic HIV Vaccine Targeting Glycopeptide Neutralization Epitopes$460,402
R01 · FY2015 · AI · contact PI
Covergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$296,400
R01 · FY2015 · GM · contact PI
Synthetic HIV Vaccine Targeting Glycopeptide Neutralizing Epitopes$485,220
R01 · FY2014 · AI · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$299,325
R01 · FY2014 · GM · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$221,898
R01 · FY2014 · GM · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$79,143
R01 · FY2014 · GM · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$299,325
R01 · FY2013 · GM · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$289,500
R01 · FY2013 · GM · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$300,000
R01 · FY2012 · GM · contact PI
Synthetic Variable Domain Glycopeptides for Neutralizing Epitope Characterization$230,250
R21 · FY2012 · AI · contact PI
Synthesis and Function of Antibody Fc Domain Glycoforms$300,000
R01 · FY2011 · GM · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$282,150
R01 · FY2010 · GM · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$525,000
R01 · FY2009 · GM · contact PI
HIV-1 Glycopeptides as Immunogens$353,635
R01 · FY2009 · AI · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$285,000
R01 · FY2009 · GM · contact PI
HIV-1 Glycopeptides as Immunogens$353,635
R01 · FY2008 · AI · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$285,000
R01 · FY2008 · GM · contact PI
HIV-1 Glycopeptides as Immunogens$297,000
R01 · FY2007 · AI · contact PI
Enzymatic Transglycosylation for N-Glycopeptide Synthesis$218,475
R01 · FY2007 · GM · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$137,349
R01 · FY2007 · GM · contact PI
HIV-1 Glycopeptides as Immunogens$50,961
R01 · FY2007 · AI · contact PI
Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins$12,525
R01 · FY2007 · GM · contact PI
HIV-1 Glycopeptides as Immunogens$371,250
R01 · FY2006 · AI · contact PI
Enzymatic Transglycosylation for N-Glycopeptide Synthesis$222,750
R01 · FY2006 · GM · contact PI
Novel Vaccine Targeting the Sugar Coat of HIV-1$222,750
R21 · FY2004 · AI
Multivalent gp41 Peptides as Novel Immunogens$222,750
R21 · FY2004 · AI
Novel Vaccine Targeting the Sugar Coat of HIV-1$222,750
R21 · FY2003 · AI
Multivalent gp41 Peptides as Novel Immunogens$222,750
R21 · FY2003 · AI